Market News AIOpen the app

PCRX stock news · Pacira BioSciences

Stories about Pacira BioSciences (PCRX) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for PCRX

Follow Pacira BioSciences (PCRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PCRX
Free on the App Store and Google Play, or on the web.
  1. Oct 8, 2026, 1:13 PM ET · Market

    On Thursday, 12 health care stocks saw big changes in their prices during the day.

    Neutral

    Pacira shares rose 44% in Thursday's session, but the article gives no reason for the move or new company news. I read this as no change to Pacira's business outlook.

  2. Oct 8, 2026, 12:58 PM ET · Deal

    Viatris is spending a lot of money to buy Pacira, which makes non-opioid pain medicines.

    Good for PCRX

    Pacira shareholders are set to receive $36.50 per share in cash. The deal still needs regulatory clearance and shareholder approval, so the payment depends on completion.

  3. Oct 8, 2026, 9:32 AM ET · Deal

    Pacira BioSciences, Inc. has agreed to merge with Viatris Inc. in a big deal.

    Good for PCRX

    Pacira agreed to a cash sale at $36.50 per share. This favors Pacira shareholders, though the deal still needs enough shares tendered and regulatory clearance.